Glaxosmithkline has
resolved the manufacturing issue
that resulted in the recall and
subsequent medicine shortage of
Zovirax Ophthalmic ointment (3%
aciclovir), according to an update
posted by the TGA yesterday.
The registered product is
now available through the
normal supply chains, while the
unapproved products which were
made available as alternatives
(AciVision and Virgan) due to
the shortage are no longer
available under section 19A of the
Therapeutic Goods Act 1989.
The initial recall was related to
metal particles found in 11 batches
of Zovirax (PD 28 Oct 2014).The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.